Search

Displaying results 6461 - 6470 of 10000 in total
  1. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.

    Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoin
  2. Drug

    COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB16520
    Experimental

    COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen

  3. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  4. Drug

    Ginseng

    go.drugbank.com/drugs/DB01404
    ApprovedInvestigationalNutraceutical

    Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties

    Synonyms: Ren shen, Ren seng rootMixtures: GINSENG-E CAPSULE
  5. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

    Synonyms: Sn Mesoporphyrin
  6. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  7. Drug

    TBX-3400

    go.drugbank.com/drugs/DB17370
    Investigational

    TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.

  8. Drug

    ATL-104

    go.drugbank.com/drugs/DB05670
    Investigational

    In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.

  9. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    D-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].

  10. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl.